Sign in
Taking peopleNo phase

Focused ultrasound compared with surgery for womb fibroids that cause symptoms

Compares HIFU with myomectomy surgery in women with symptomatic uterine fibroids.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids
Status
Recruiting
People taking part
112 people, planned
Started
6 Feb 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High-Intensity Focused Ultrasound (HIFU)
  • myomectomy
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 to 50 with uterine fibroids that cause symptoms. It compares HIFU, a focused ultrasound treatment, with myomectomy, surgery to remove the fibroids.

Age
18 to 50 years
Sex
Women only
Disease stage
Fibroids that cause heavy periods, pressure or pelvic pain. The main fibroid is in the muscle wall of the womb and measures ≥ 3cm (1.2 in) and ≤ 10cm (3.9 in) on imaging. Uterine size ≤18 weeks on physical exam. Before or around menopause, with FSH less than 25 mIU/ml. BMI < 33 kg/m2 or abdominal wall thickness < 5 cm (2 in).
Earlier treatment
People who had radiation to the pelvis cannot join.
Biomarker or test result
FSH less than 25 mIU/ml

Main reasons for not taking part

  • Pregnancy, breastfeeding or menopause
  • Other pelvic masses or disease, such as endometriosis, ovarian tumour, pelvic infection or adenomyosis, or possible cancer of the womb
  • Fibroids that doubled in size in 6 months, or fibroids in the cervix or broad ligament
  • Past or current blood clots or stroke, clotting problems, or medicines that affect clotting
  • Cannot have MRI, cannot lie face down for more than 2 hours, severe obesity, or a large scar on the belly in the treatment path

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age 18 - 50 years-old
  • Pre or peri menopausal with FSH less than 25 mIU/ml
  • BMI < 33 kg/m2 or abdominal wall thickness < 5 cm
  • Uterine size ≤18 weeks based on physical exam assessment
  • Dominant intramural fibroid ≥ 3cm and ≤ 10cm on imaging
  • Symptomatic fibroids cause menorrhagia, pressure, or pelvic pain
  • Willing and able to give informed consent

Who cannot take part

  • Coagulation problem or using medication which affect clotting function
  • Patient with other pelvic mass indicated by history or magnetic resonance imaging (MRI) such as endometriosis, abnormal adnexal mass, ovarian tumor, acute or chronic pelvic inflammatory disease
  • Uterine premalignant or malignant pathologies or pathology other than uterine fibroid cannot be ruled out through detailed clinical assessment and investigation including MRI
  • History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)
  • History of pelvic irradiation
  • Morbid obesity
  • Inability to lie in a prone position for more than 2 hours
  • Extensive abdominal scar on the acoustic channel
  • Women with pregnancy, lactation or menopause
  • Rapid growth of fibroids, defined as a doubling in size in 6 months
  • Pedunculated submucosal or subserosal fibroid of size ≧5cm and with a stalk less than 25% of the maximal fibroid diameter
  • Cervical/ broad ligament fibroid
  • Contraindication to MRI due to severe claustrophobia or implanted metallic device
  • Co-existing adenomyosis

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if High-Intensity Focused Ultrasound (HIFU) is as effective as myomectomy for treating symptomatic uterine fibroids in women aged 18 to 50. The main questions it aims to answer are:

Read full original descriptionShow less

Is HIFU as effective as myomectomy in improving quality of life for women with uterine fibroids? How do the recovery times and complications compare between HIFU and myomectomy? Researchers will compare the outcomes of women receiving HIFU treatment to those undergoing myomectomy to see if HIFU offers similar or better results with fewer complications.

Participants will:

Undergo an initial medical assessment, including ultrasounds and blood tests. Receive either HIFU treatment or myomectomy based on random assignment. Complete questionnaires about their symptoms and quality of life before treatment and at follow-up visits (3 and 6 months post-treatment).

Be monitored for any complications and recovery progress during follow-up.

The 2 groups in the trial

  • HIFU groupExisting treatment, for comparison

    All women in the HIFU group will undergo pelvic MRI scans, including T1- and T2-weighted imaging, for fibroid localization and treatment planning. The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W, with treatment energy tailored to participant feedback and ultrasound imaging. Post-procedure, participants will be monitored for 4-6 hours, with discharge criteria including dietary tolerance and urination. Data on pain, skin condition, and adverse events will be collected. Before discharge, participants will complete a Client Satisfaction questionnaire and will receive analgesics, along with instructions to document menstrual cycles using the PBAC chart.

    Treatment: High-Intensity Focused Ultrasound (HIFU)

  • Myomectomy groupPlacebo, for comparison

    Myomectomy will be performed using laparoscopic, open, or hysteroscopic techniques by accredited HKCOG gynecologists. Key metrics such as blood loss, intraoperative and postoperative complications, whether the endometrial cavity was entered, length of hospital stay, need for blood transfusion, and readmissions will be meticulously recorded. A complete blood count will be assessed approximately 6 hours post-surgery. Patients will be monitored for blood pressure and pulse per departmental protocol. Typically, those undergoing hysteroscopic myomectomy are discharged the same day, while laparoscopic or open myomectomy patients are discharged within 1 to 3 days. Before discharge, women will complete a Client Satisfaction questionnaire and will receive analgesics, along with instructions to document their menstrual cycle, flow, and dysmenorrhea using the PBAC chart.

    Treatment: myomectomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial of High-Intensity Focused Ultrasound (HIFU) Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids
Plain-language title
Focused ultrasound compared with surgery for womb fibroids that cause symptomsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06692335, who can take part
Record updated
27 March 2026